Details for Patent: 8,354,427

Which drugs does patent 8,354,427 protect, and when does it expire?

Patent 8,354,427 protects KALYDECO, SYMDEKO (COPACKAGED), and TRIKAFTA (COPACKAGED), and is included in four NDAs.

This patent has one hundred and twenty-one patent family members in twenty-six countries.

Summary for Patent: 8,354,427

Title:	Modulators of ATP-binding cassette transporters
Abstract:	The present invention relates to modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
Inventor(s):	Van Goor; Fredrick (San Diego, CA)
Assignee:	Vertex Pharmaceutical Incorporated (Cambridge, MA)
Application Number:	12/635,927
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,354,427

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-003	Apr 29, 2019		RX	Yes	No						METHOD OF TREATING CYSTIC FIBROSIS
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-003	Apr 29, 2019		RX	Yes	No						METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, THE PATIENT HAVING A R117H MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-003	Apr 29, 2019		RX	Yes	No						TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO

International Family Members for US Patent 8,354,427

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005258320
Australia	2010249302
Australia	2010251787